HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib
Expert Perspectives · Keira Smith · 2026-04-03
The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.
Impact on Practice and Patient Outcomes
Ms. Sandy described the approval as practice-changing: “This is the first HER2 therapy that has moved to the front line.” She noted the convenience advantage of having a pill that can be taken once daily at home, compared with IV therapies that require time in the clinic. Efficacy data are also compelling: a 76% overall response rate, with 64% of the patients still responding at six months or longer. She added that these outcomes are “better than a platinum-based chemotherapy regimen that we would typically use upfront” and “certainly more tolerable as a pill.”
Safety Profile and Management Strategies
While targeted and oral, zongertinib still requires monitoring. Ms. Sandy outlined key risks: hepatic dysfunction and liver injury, left ventricular ejection fraction (LVEF) dysfunction, and interstitial lung disease (ILD). While rates of ILD were low at 2%, the most common side effect is diarrhea, experienced by 56% of patients. Grade 3-4 diarrhea was only seen in 2.8%, and most cases can be managed with over-the-counter loperamide. Other effects include nausea (25%) and rash (32%), both largely low-grade. Liver enzyme elevations stood out, with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevations around 30% to 40%, with 5% to 10% requiring dose holds or reductions, underscoring the need for frequent lab checks.
Final Thoughts on the the Approval
Ms. Sandy summarized the broader significance of the approval: “it’s just exciting for us to finally have a first-line therapy in HER2-mutated NSCLC, especially one that comes in the way of a pill with a fairly good toxicity profile.”
Key Takeaways
Zongertinib is now approved for HER2-mutant NSCLC in any line, including frontline.
Oral, once-daily dosing offers meaningful convenience over IV options.
Strong efficacy: 76% response rate and durable responses.
Side effects are generally manageable; diarrhea is most common.
Liver function monitoring is essential due to AST/ALT elevations.
About the Speaker
Beth Sandy, MSN, CRNP, FAPO, is a Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of the University of Pennsylvania. She specializes in the treatment and supportive care of patients with lung cancer and other thoracic malignancies. Ms. Sandy has authored and coauthored numerous peer-reviewed publications, posters, and book chapters, and has been a speaker at several national and international conferences. She is a member of several professional societies and is active on committees and editorial boards for APSHO, IASLC, MASCC, ONS, and SITC.